




Goat Anti-Human IgA

Cat. No.	Format	Size
2050-01	Purified (UNLB)	1.0 mg
2050-02	Fluorescein (FITC)	1.0 mg
2050-03	Rhodamine (TRITC)	1.0 mg
2050-04	Alkaline Phosphatase (AP)	1.0 mL
2050-05	Horseradish Peroxidase (HRP)	1.0 mL
2050-07	Texas Red® (TXRD)	1.0 mg
2050-08	Biotin (BIOT)	1.0 mg
2050-09	R-phycoerythrin (PE)	0.5 mg
2050-30	Alexa Fluor® 488 (AF488)	1.0 mg
2050-31	Alexa Fluor® 647 (AF647)	1.0 mg
2050-32	Alexa Fluor® 555 (AF555)	1.0 mg



ELISA plate was coated with purified human IgA, IgG, and IgM. Immunoglobulins were detected with serially diluted Goat Anti-Human IgA-AP (SB Cat. No. 2050-04).

Description

Specificity	Reacts with the heavy chain of human IgA
Source	Pooled antisera from goats hyperimmunized with human IgA
Cross Adsorption	Human IgG and IgM; may react with IgA from other species
Purification	Affinity chromatography on human IgA covalently linked to agarose

Applications

Quality tested applications include –

ELISA ^{1-5,15}
 FLISA
 FC ^{17,18}

Other referenced applications include –

ELISPOT ^{6,7}
 IHC-FS ^{8,9,13}
 IHC-PS ^{10,11}
 ICC ¹²
 WB ^{14,15}
 IP ¹⁶
 Multiplex ^{1,19}
 Purification ^{21,22}
 Depletion ²⁰

Working Dilutions

ELISA	AP conjugate	1:2,000 – 1:4,000
	HRP conjugate	1:4,000 – 1:8,000
	BIOT conjugate	1:5,000 – 1:20,000

FLISA	FITC, TRITC, TXRD, AF488, and AF555 conjugates	1:100 – 1:400
	PE and AF647 conjugates	≤ 1 µg/mL

Flow Cytometry	FITC, BIOT, and AF488 conjugates	≤ 1 µg/10 ⁶ cells
	PE and AF647 conjugates	≤ 0.1 µg/10 ⁶ cells
	For flow cytometry, the suggested use of these reagents is in a final volume of 100 µL	

Other Applications Since applications vary, you should determine the optimum working dilution for the product that is appropriate for your specific need.

For Research Use Only. Not for Diagnostic or Therapeutic Use.

Handling and Storage

- The purified (UNLB) antibody is supplied as 1.0 mg purified immunoglobulin in 1.0 mL of borate buffered saline, pH 8.2. *No preservatives or amine-containing buffer salts added.* Store at 2-8°C.
- The fluorescein (FITC), rhodamine (TRITC), Texas Red® (TXRD), Alexa Fluor® 488 (AF488), Alexa Fluor® 555 (AF555), and Alexa Fluor® 647 (AF647) conjugates are supplied as 1.0 mg in 1.0 mL of PBS/NaN₃. Store at 2-8°C.
- The alkaline phosphatase (AP) conjugate is supplied as 1.0 mL in a stock solution of 50 mM Tris/1 mM MgCl₂/50% glycerol, pH 8.0, containing NaN₃ as preservative. Store at 2-8°C or long-term at -20°C.
- The horseradish peroxidase (HRP) conjugate is supplied as 1.0 mL in a stock solution of 50% glycerol/50% PBS, pH 7.4. No preservative added. Store at 2-8°C or long-term at -20°C.
- The biotin (BIOT) conjugate is supplied as 1.0 mg in 2.0 mL of PBS/NaN₃. Store at 2-8°C.
- The R-phycoerythrin (PE) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN₃ and a stabilizing agent. Store at 2-8°C. **Do not freeze!**
- Protect fluorochrome-conjugated forms from light. Reagents are stable for the period shown on the label if stored as directed.

Warning

Some reagents contain sodium azide. Please refer to product specific SDS.

References

1. Dasso J, Lee J, Bach H, Mage RG. A comparison of ELISA and flow microsphere-based assays for quantification of immunoglobulins. *J Immunol Methods*. 2002;263:23-33. (ELISA, Multiplex)
2. Wang J, Anders RA, Wu Q, Peng D, Cho JH, Sun Y, et al. Dysregulated LIGHT expression on T cells mediates intestinal inflammation and contributes to IgA nephropathy. *J Clin Invest*. 2004;113:826-35. (ELISA)
3. Yang M, Li F, Xie X, Wang S, Fan J, CagA, a major virulence factor of *Helicobacter pylori*, promotes the production and underglycosylation of IgA1 in DAKIKI cells. *Biochem Biophys Res Commun*. 2014;444:276-81. (ELISA)
4. Novak D, Svennerholm A. A comparison of seasonal variations in rotavirus antibodies in the breast milk of Swedish and Bangladeshi mothers. *Acta Paediatr*. 2015;104:247-51. (ELISA)
5. Alam MJ, Rashid MM, Kabir Y, Raqib R, Ahmad SM. On birth single dose live attenuated OPV and BCG vaccination induces gut cathelicidin LL37 responses at 6 week of age: a natural experiment. *Vaccine*. 2015;33:18-21. (ELISA)
6. Ruprecht CR, Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. *Eur J Immunol*. 2006;36:810-6. (ELISPOT)
7. Ramani S, Neill FH, Opekun AR, Gilger MA, Graham DY, Estes MK, et al. Mucosal and cellular immune responses to Norwalk virus. *J Infect Dis*. 2015 Jan 29. pii: jiv053. [Epub ahead of print]. (ELISPOT)
8. Forshammer J, Isaksson S, Strid H, Stotzer P, Sjövall H, Simrén M, et al. A pilot study of colonic B cell pattern in irritable bowel syndrome. *Scand J Gastroenterol*. 2008;43:1461-6. (IHC-FS)
9. Xu W, Santini PA, Matthews AJ, Chiu A, Plebani A, He B, et al. Viral double-stranded RNA triggers Ig class switching by activating upper respiratory mucosa B cells through an innate TLR3 pathway involving BAFF. *J Immunol*. 2008;181:276-87. (IHC-FS)
10. Rowley AH, Shulman ST, Mask CA, Finn LS, Terai M, Baker SC, et al. IgA plasma cell infiltration of proximal respiratory tract, pancreas, kidney, and coronary artery in acute Kawasaki disease. *J Infect Dis*. 2000;182:1183-91. (IHC-PS)
11. Liu D, Jiang W, Liu P. Reduction of the amount of intestinal secretory IgA in fulminant hepatic failure. *Braz J Med Biol Res*. 2011;44:477-82. (IHC-PS)
12. Suzuki H, Moldoveanu Z, Hall S, Brown R, Vu HL, Novak L, et al. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. *J Clin Invest*. 2008;118:629-39. (ICC)
13. Puga I, Cols M, Barra CM, He B, Cassis L, Gentile M, et al. B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. *Nat Immunol*. 2012;13:170-80 (IHC-FS)
14. Berthelot L, Papista C, Maciel TT, Biarnes-Pelicot M, Tissandie E, Wang PH, et al. Transglutaminase is essential for IgA nephropathy development acting through IgA receptors. *J Exp Med*. 2012;209:793-806. (WB)
15. Pascal V, Laffleur B, Debin A, Cuvillier A, van Egmond M, Drocourt D, et al. Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells. *Haematologica*. 2012;97:1686-94. (ELISA, WB)
16. Santiago T, Kulemzin SV, Reshetnikova ES, Chikaev NA, Volkova OY, Mechetina LV, et al. FCRLA is a resident endoplasmic reticulum protein that associates with intracellular Igs, IgM, IgG and IgA. *Int Immunol*. 2011;23:43-53. (IP)
17. He B, Santamaria R, Xu W, Cols M, Chen K, Puga I, et al. The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. *Nat Immunol*. 2010;11:836-45. (FC)
18. Skrede S, Steinsland H, Sommerfelt H, Aase A, Brandtzaeg P, Langeland N, et al. Experimental infection of healthy volunteers with enterotoxigenic *Escherichia coli* wild-type strain TW10598 in a hospital ward. *BMC Infect Dis*. 2014;14:482. (FC)
19. Gu A, Mo H, Bei J, Xie Y, Chen L, Feng Q, et al. Evaluation of antibodies against different Epstein-Barr virus nuclear antigen 1 peptides in diagnosis of nasopharyngeal carcinoma. *Clin Vaccine Immunol*. 2009;16:592-3. (Multiplex)
20. Palaia JM, McConnell M, Achenbach JE, Gustafson CE, Stoermer KA, Nolan M, et al. Neutralization of HIV subtypes A and D by breast milk IgG from women with HIV infection in Uganda. *J Infect*. 2014;68:264-72. (Depletion)
21. Janoff EN, Fasching C, Orenstein JM, Rubins JB, Opstad NL, Dalmasso AP. Killing of *Streptococcus pneumoniae* by capsular polysaccharide-specific polymeric IgA, complement, and phagocytes. *J Clin Invest*. 1999;104:1139-47. (Purification)
22. Meinke A, Henics T, Hanner M, Minh DB, Nagy E. Antigenome technology: a novel approach for the selection of bacterial vaccine candidate antigens. *Vaccine*. 2005;23:2035-41. (Purification)

Texas Red® is a registered trademark of Molecular Probes, Inc.

Alexa Fluor® 488, 647, and 555 are provided under an Intellectual property license from Life Technologies Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. For information on purchasing a license to this product for any other use, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@lifetech.com.

TB2050
22-Jun-21

Corporate Offices: 160 Oxmoor Blvd • Birmingham, AL 35209 • USA Mailing Address: P.O. Box 26221 • Birmingham, AL 35260 • USA

Tel: 205.945.1774 • U.S. and Canada: 800.722.2255 • Fax: 205.945.8768

Email: info@southernbiotech.com • Website: www.southernbiotech.com